Abstract
The aim of this study was to evaluate the synthetic C6 peptide test as a first-line test in a two-tiered scheme for Borrelia serology in a clinically well-characterized population of patients with Lyme borreliosis in Kalmar County, Sweden. The study population consisted of a prospective group (n = 200), a control group (n = 255), and a retrospective group (n = 29). The test panel consisted of the Immunetics Quick ELISA C6 Borrelia assay kit (Immunetics, Cambridge, MA, USA), the Virotech Borrelia burgdorferi ELISA (Genzyme Virotech, Rüsselsheim, Germany), and the Liaison Borrelia CLIA (DiaSorin, Saluggia, Vercelli, Italy). Seroprevalence among 200 healthy blood donors was significantly lower in the C6 test (8%) compared to the Virotech ELISA (14%) and the Liaison CLIA (12%). In convalescent sera (2–3 months and 6 months post infection) from 158 patients with erythema migrans, the seropositivity in the C6 test was also significantly lower compared to both the Virotech ELISA and the Liaison CLIA. Serosensitivity in the acute phase of erythema migrans and other clinical manifestations of borreliosis did not differ significantly between the C6 test and the Virotech ELISA or the Liaison CLIA. Overall, a positive C6 test seems to correlate well with acute borreliosis. Cross-reactivity was lower in the C6 test in sera positive for Epstein-Barr virus infection as compared to the Virotech ELISA. This study supports the use of the C6 test as a screening test for borreliosis, in endemic areas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringer A, Elmrud H, Carlsson M, Runehagen A, Svanborg C, Norrby R (1995) An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 333:1319–1327
Berglund J, Eitrem R (1993) Tick-borne borreliosis in the archipelago of southern Sweden. Scand J Infect Dis 25:67–72
Bunikis J, Olsen B, Westman G, Bergström S (1995) Variable serum immunoglobulin responses against different Borrelia burgdorferi sensu lato species in a population at risk for and patients with Lyme disease. J Clin Microbiol 33:1473–1478
Prasad A, Sankar D (1999) Overdiagnosis and overtreatment of Lyme neuroborreliosis are preventable. Postgrad Med J 75:650–656
Goossens HA, van den Bogaard AE, Nohlmans MK (1999) Evaluation of fifteen commercially available serological tests for diagnosis of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 18:551–560
Ekerfelt C, Ernerudh J, Forsberg P, Jonsson AL, Vrethem M, Arlehag L, Forsum U (2004) Lyme borreliosis in Sweden—diagnostic performance of five commercial Borrelia serology kits using sera from well-defined patient groups. APMIS, Acta Pathol Microbiol Immunol Scand 112:74–78
Jansson C, Carlsson SA, Granlund H, Wahlberg P, Nyman D (2005) Analysis of Borrelia burgdorferi IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA. Clin Microbiol Infect 11:147–150
Liang FT, Aberer E, Cinco M, Gern L, Hu CM, Lobet YN, Ruscio M, Voet Jr PE, Weynants VE, Philipp MT (2000) Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL. J Infect Dis 182:1455–1462
Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT (1999) Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE. J Clin Microbiol 37:3990–3996
Philipp MT, Bowers LC, Fawcett PT, Jacobs MB, Liang FT, Marques AR, Mitchell PD, Purcell JE, Ratterree MS, Straubinger RK (2001) Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J Infect Dis 184:870–878
Anonymous (2001) Manual for Virotech Western Blot Borrelia burgdorferi EcoBlot IgG/IgM. Genzyme Virotech, Rüsselsheim, Germany
Marconi RT, Garon CF (1992) Development of polymerase chain reaction primer sets for diagnosis of Lyme disease and for species-specific identification of Lyme disease isolates by 16S rRNA signature nucleotide analysis. J Clin Microbiol 11:2830–2834
Anonymous (2003) Manual for Immunetics Quick ELISA C6 Borrelia assay kit. Immunetics, Cambridge, MA, USA
Anonymous (2003) Manual for Virotech Borrelia burgdorferi ELISA IgG/IgM testkit. Genzyme Virotech, Rüsselsheim, Germany
Anonymous (2004) Manual for Liaison Borrelia IgM (310890), IgG (310880). DiaSorin, Saluggia (Vercelli), Italy
Anonymous (2005) Manual for IDEIA Lyme Neuroborreliosis. DakoCytomation, Cambridgeshire, UK
Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell, London, p 677
Centers for Disease Control and Prevention (1995) Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. Morb Mortal Wkly Rep 44:590–591
Brouqui P, Bacellar F, Baranton G, Birtles RJ, Bjöersdorff A, Blanco JR, Caruso G, Cinco M, Fournier PE, Francavilla E et al (2004) Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect 10:1108–1132
Acknowledgement
The study was conducted with support from the Medical Research Council of Southeast Sweden. We are most grateful to all involved nurses and physicians in Kalmar County for their help with patients and sample collection. The experiments of this study comply with current laws of Sweden.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tjernberg, I., Krüger, G. & Eliasson, I. C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden. Eur J Clin Microbiol Infect Dis 26, 37–42 (2007). https://doi.org/10.1007/s10096-006-0239-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-006-0239-3